PMID- 34660261
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231107
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With 
      Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France.
PG  - 675609
LID - 10.3389/fonc.2021.675609 [doi]
LID - 675609
AB  - We analyzed demographic characteristics, comorbidities and patterns of treatment 
      with tyrosine kinase inhibitors (TKIs) in a cohort of 3,633 incident cases of 
      chronic myeloid leukemia (CML) identified across France from 1 January 2011 to 31 
      December 2014. Patients were identified through a specific algorithm in the 
      French Healthcare Data System and were followed up 12 months after inclusion in 
      the cohort. The estimated incidence rate of CML for this period in France was 
      1.37 per 100,000 person-years (95% Confidence Interval 1.36-1.38) and was higher 
      in men, with a peak at age 75-79 years. At baseline, the median age of the cohort 
      was 60 years (Inter Quartile Range 47-71), the Male/Female ratio was 1.2, and 25% 
      presented with another comorbidity. Imatinib was the first-line TKI for 77.6% of 
      the patients, followed by nilotinib (18.3%) and dasatinib (4.1%). Twelve months 
      after initiation, 86% of the patients remained on the same TKI, 13% switched to 
      another TKI and 1% received subsequently three different TKIs. During the 
      follow-up, 23% discontinued and 52% suspended the TKI. Patients received a mean 
      of 16.7 (Standard Deviation (SD) 9.6) medications over the first year of 
      follow-up, and a mean of 2.7 (SD 2.3) concomitant medications on the day of first 
      TKI prescription: 24.4% of the patients received allopurinol, 6.4% proton pump 
      inhibitors (PPI) and 6.5% antihypertensive agents. When treatment with TKI was 
      initiated, incident CML patients presented with comorbidities and polypharmacy, 
      which merits attention because of the persistent use of these concomitant drugs 
      and the potential increased risk of drug-drug interactions.
CI  - Copyright (c) 2021 Pajiep, Conte, Huguet, Gauthier, Despas and Lapeyre-Mestre.
FAU - Pajiep, Marie
AU  - Pajiep M
AD  - Service de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire 
      de Toulouse, Toulouse, France.
AD  - Equipe PEPSS (Pharmacologie en Population, cohorteS, biobanqueS), Centre 
      d'Investigation Clinique 1436, INSERM, Universite de Toulouse 3, Toulouse, 
      France.
FAU - Conte, Cecile
AU  - Conte C
AD  - Service de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire 
      de Toulouse, Toulouse, France.
FAU - Huguet, Francoise
AU  - Huguet F
AD  - Department d'Hematologie, Institut Universitaire du Cancer de Toulouse, Centre 
      Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France.
FAU - Gauthier, Martin
AU  - Gauthier M
AD  - Department d'Hematologie, Institut Universitaire du Cancer de Toulouse, Centre 
      Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France.
FAU - Despas, Fabien
AU  - Despas F
AD  - Service de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire 
      de Toulouse, Toulouse, France.
AD  - Equipe PEPSS (Pharmacologie en Population, cohorteS, biobanqueS), Centre 
      d'Investigation Clinique 1436, INSERM, Universite de Toulouse 3, Toulouse, 
      France.
FAU - Lapeyre-Mestre, Maryse
AU  - Lapeyre-Mestre M
AD  - Service de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire 
      de Toulouse, Toulouse, France.
AD  - Equipe PEPSS (Pharmacologie en Population, cohorteS, biobanqueS), Centre 
      d'Investigation Clinique 1436, INSERM, Universite de Toulouse 3, Toulouse, 
      France.
LA  - eng
PT  - Journal Article
DEP - 20210930
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8515137
OTO - NOTNLM
OT  - chronic myeloid leukemia
OT  - comorbidities
OT  - first line treatment
OT  - incidence
OT  - polypharmacy
OT  - tyrosine kinase inhibitors (TKI)
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/19 06:00
MHDA- 2021/10/19 06:01
PMCR- 2021/01/01
CRDT- 2021/10/18 09:06
PHST- 2021/03/03 00:00 [received]
PHST- 2021/09/13 00:00 [accepted]
PHST- 2021/10/18 09:06 [entrez]
PHST- 2021/10/19 06:00 [pubmed]
PHST- 2021/10/19 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.675609 [doi]
PST - epublish
SO  - Front Oncol. 2021 Sep 30;11:675609. doi: 10.3389/fonc.2021.675609. eCollection 
      2021.